TIL cells

DRUG2 trials

Sponsors

Leids Universitair Medisch Centrum (LUMC)

Conditions

Metastatic MelanomaOvarian carcinoma

Phase 1

(ACTME) Adoptive TIL therapy with low-dose PEG-IFNa plus nivolumab in metastatic melanoma

Not yet recruitingCTIS2024-516125-31-02

Leids Universitair Medisch Centrum (LUMC)Metastatic Melanoma

Target: 58Updated: 2025-08-12

OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

Not yet recruitingCTIS2025-522659-24-00

Leids Universitair Medisch Centrum (LUMC)Ovarian carcinoma

Target: 30Updated: 2025-12-03